Dapagliflozin and Saxagliptin Make a Dazzling Duo


The latest news in the fight against type 2 diabetes highlights Dapagliflozin and Saxagliptin as the latest dazzling duo. Known as the brand name medications Farxiga {Dapagliflozin} and Onglyza {Saxagliptin} these powerhouse drugs have proven themselves in Phase lll trials. Data recently released from the 534 patient, three-arm trial demonstrated that the combination treatment of Dapagliflozin and Saxagliptin, alongside Metformin was superior to either Dapagliflozin and Metformin or Saxagliptin and Metformin adjunctively. The 24 week Phase lll trial involved patients who were not gleaning adequate control of their blood sugar from metformin only. Results were telling in the patient population who received Dapagliflozin, Saxagliptin and Metformin, with more patients achieving their blood sugar goal of less than 7% HbA1c by the conclusion of the trial. The HbA1c on average dropped 1.47 percent in the patients who were dosed with metformin and the dynamic diabetes duo. The use of the DPP-4 inhibitor Saxagliptin, alongside the SGLT-2 inhibitor Dapagliflozin appears to be an effectual treatment option for patients who have difficulty obtaining optimal blood sugar control.

Dapagliflozin and Saxagliptin

glycated hemoglobinThe FDA approved Dapagliflozin for the treatment of type 2 diabetes mellitus on January 13, 2014 as a once daily oral medication. The typical starting dose for most patients is 5 milligrams of Dapagliflozin, taken once daily, but some patients may need up to 10 milligrams once a day to achieve blood sugar control. Two dozen comprehensive clinical trials of Dapagliflozin have taken place with over than 11,000 patients who suffer from type 2 diabetes. Patients who were dosed with the combination of Dapagliflozin and Metformin displayed tangible reductions in their baseline HbA1c levels, and showed minimal adverse effects such as hypoglycemia. Patients who received Saxagliptin in copious studies found success in decreasing their blood sugar spikes on a daily basis. The clinical trial participants dosed with both Saxagliptin, either 2.5 milligrams or 5 milligrams once daily, as well as Metformin achieved exemplary glucose control, and proved to be at no greater risk for cardiovascular events either. This new duo/trio of anti-diabetic medications looks extremely promising for the 440 million people predicted to have type 2 diabetes by 2030.

LGM Pharma provides Dapagliflozin CAS# 461432-26-8 and Saxagliptin CAS# 361442-04-8, as well as  Metformin CAS# 657-24-9 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: